Spectra Science Optical Biopsy Colorectal Cancer Device Awaits FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Spectra Science says it is "optimistic" that FDA's Gastroenterology and Urology Devices Panel will review, at its scheduled Nov. 18-19 meeting, the company's Optical Biopsy system (OBS) for detection of colorectal cancer.